menu
    • menu
    [{"orgOrder":0,"company":"Beijing Tiantan Hospital","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Beijing Tiantan Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Tiantan Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Beijing Tiantan Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"University of Magdeburg","sponsor":"Sirtex Medical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Oncology","graph2":"Phase II","graph3":"University of Magdeburg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Magdeburg \/ Sirtex Medical","highestDevelopmentStatusID":"8","companyTruncated":"University of Magdeburg \/ Sirtex Medical"},{"orgOrder":0,"company":"Ipekyolu Ilac","sponsor":"Istanbul University - Cerrahpasa","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TURKEY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Ipekyolu Ilac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ipekyolu Ilac \/ Istanbul University - Cerrahpasa","highestDevelopmentStatusID":"8","companyTruncated":"Ipekyolu Ilac \/ Istanbul University - Cerrahpasa"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Oncology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ AstraZeneca"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Silk Road Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Silk Road Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silk Road Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Silk Road Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Silk Road Therapies \/ Soligenix","highestDevelopmentStatusID":"8","companyTruncated":"Silk Road Therapies \/ Soligenix"},{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Poolbeg Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Silk Road Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Silk Road Therapies \/ Poolbeg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Silk Road Therapies \/ Poolbeg Pharma"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"Adenosine A2 receptor | 3',5'-cyclic phosphodiesterase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Prokrea BCN, S.L.","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"PDEs|TNF-alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Prokrea BCN, S.L.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Prokrea BCN, S.L. \/ TFS Trial Form Support","highestDevelopmentStatusID":"6","companyTruncated":"Prokrea BCN, S.L. \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Prokrea BCN, S.L.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"PDEs|TNF-alpha","graph1":"Endocrinology","graph2":"Phase II","graph3":"Prokrea BCN, S.L.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Prokrea BCN, S.L. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prokrea BCN, S.L. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-

    Menu

    1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Prokrea BCN, S.L.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Prokrea BCN, S.L.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : TFS Trial Form Support

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pentoxifylline PKB171 Gel in Healthy Females Volunteers

                            Details : PKB171 (Pentoxifylline) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : PKB171

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 12, 2025

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : TFS Trial Form Support

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Prokrea BCN, S.L.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Prokrea BCN, S.L.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PKB171 Against Placebo in Couples with Asthenozoospermia Who Wish to Conceive

                            Details : PKB171 (Pentoxifylline) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Infertility, Male.

                            Product Name : PKB171

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 22, 2025

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University Health Network, Toronto

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University Health Network, Toronto

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Canc...

                            Details : Pentoxifylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Silk Road Therapies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Silk Road Therapies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Poolbeg Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate

                            Details : Through the agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Trental (pentoxifylline), for oral ulcers in patients suffering from behcet's disease.

                            Product Name : Trental

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Poolbeg Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

                            Details : Trental-Generic (pentoxifylline) is an oral small molecule drug. It is now approved for the treatment of chronic occlusive arterial disease of the limbs.

                            Product Name : Trental-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 23, 2024

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible

                            Details : Pentoxifylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoradionecrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 26, 2023

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Silk Road Therapies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Silk Road Therapies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Soligenix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifyll...

                            Details : The option agreement grants Soligenix the right to acquire a novel topical formulation of SRT001 (pentoxifylline), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD).

                            Product Name : Trental

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 01, 2023

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Soligenix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Beijing Tiantan Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Beijing Tiantan Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)

                            Details : Pentoxifylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cerebral Small Vessel Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 17, 2022

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Silk Road Therapies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Silk Road Therapies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers

                            Details : Pentoxifylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Behcet Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 04, 2019

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ipekyolu Ilac

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ipekyolu Ilac

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Istanbul University - Cerrahpasa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers

                            Details : Pentoxifylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Behcet Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 25, 2019

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Istanbul University - Cerrahpasa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth